Compare
AbbVie vs Protagonist Therapeutics (ABBV vs PTGX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Protagonist Therapeutics (PTGX) +69.5%; so far this year the figures are +27.5% and +51.2%.
AbbVie is the larger company by market value, about 59.7 times the size of Protagonist Therapeutics.
On trailing earnings, ABBV trades at 50.1 times and PTGX at 28.0 times.
Revenue grew +10.7% at ABBV and +163.7% at PTGX over the last year.
ABBV yields 2.38%. PTGX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | PTGX | |
|---|---|---|
| Price | $291.31 | $132.04 |
| 1-day | +1.07% | -2.38% |
| YTD | +27.49% | +51.18% |
| 1 year | +34.39% | +69.54% |
| 3 years | +104.47% | +773.86% |
| Market cap | $514.9B | $8.6B |
| P/E | 50.1 | 28.0 |
| P/S | 7.80 | 15.62 |
| P/B | — | 7.94 |
| Revenue growth | +10.70% | +163.70% |
| EPS growth | +340.20% | +624.60% |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | 62.0 |
| ROE % | — | 31.5 |
| Debt / equity | — | 0.01 |
| FCF yield % | 3.7 | 1.3 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.93 |
| RSI (14) | 59.7 | 39.0 |
| Technical rating |